Olivier Jarry - DarioHealth Corp President and Chief Commercial Officer
| DRIO Stock | USD 0.72 0.05 7.46% |
President
Mr. Olivier Jarry is President and Chief Commercial Officer of the Company. Mr. Jarry has served on the Companys Advisory Board and as a Strategic Advisory consultant since 2017. Between 2015 and 2016, he served as Senior VicePresident of the Consumer Sector and Officer at Intrexon Corporationration, a biotechnology company focused on engineering biological systems to enable DNAbased control over the function and output of living cells. Prior to Intrexon, from 2011 to 2012, Mr. Jarry served as the Head of Strategy, Operations and Market Access, focusing on Emerging Markets, for BristolMyers Squibb, where he oversaw the product launch and growth of innovative medicines relating to oncology, virology, rheumatology, cardiovascular, and diabetes. Prior to that, between 2009 and 2010, Mr. Jarry served as the Global Business Unit Head of Bayer Diabetes Care, a division of Bayer HealthCare Pharmaceuticals LLC. Prior to his time at Bayer HealthCare, from 2001 to 2009, Mr. Jarry served in several leadership roles at Novartis International AG, including working as Global Division Head of Strategy, Business Development Licensing at Novartis Headquarters in Switzerland, Senior Vice President and Region Head for Latin America and for AsiaPacific for Novartis Consumer Health Division, Head of India Rural Business and Head of WesternEastern Europe, Russia, CIS Vaccines division since 2018.
| Age | 63 |
| Tenure | 6 years |
| Professional Marks | MBA |
| Address | 122 W 57th St,, New York, NY, United States, 10019 |
| Phone | 972 477 0637 7 |
| Web | https://www.dariohealth.com |
DarioHealth Corp Management Efficiency
The company has return on total asset (ROA) of (0.3474) % which means that it has lost $0.3474 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7491) %, meaning that it created substantial loss on money invested by shareholders. DarioHealth Corp's management efficiency ratios could be used to measure how well DarioHealth Corp manages its routine affairs as well as how well it operates its assets and liabilities. As of the 28th of November 2024, Return On Tangible Assets is likely to drop to -1.26. In addition to that, Return On Capital Employed is likely to drop to -0.7. At this time, DarioHealth Corp's Intangibles To Total Assets are very stable compared to the past year. As of the 28th of November 2024, Debt To Assets is likely to grow to 0.31, while Other Current Assets are likely to drop about 1 M.Similar Executives
| Found 1 records | PRESIDENT Age | ||
| Luciano Bonanni | Fonar | 69 | |
Management Performance
| Return On Equity | -0.75 | ||||
| Return On Asset | -0.35 |
DarioHealth Corp Leadership Team
Elected by the shareholders, the DarioHealth Corp's board of directors comprises two types of representatives: DarioHealth Corp inside directors who are chosen from within the company, and outside directors, selected externally and held independent of DarioHealth. The board's role is to monitor DarioHealth Corp's management team and ensure that shareholders' interests are well served. DarioHealth Corp's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, DarioHealth Corp's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Tomer BenKiki, Chief Officer | ||
| Zvi CPA, Treasurer CFO | ||
| Josh Fischer, Senior Compliance | ||
| Dov Oppenheim, CoFounder Chief | ||
| Brian Harrigan, Senior Sales | ||
| Richard Anderson, President | ||
| Claudia Levi, Content Manager | ||
| Jean Muyl, Head America | ||
| Zvi David, Treasurer CFO | ||
| Kat Parrella, Investor Manager | ||
| Dror Bacher, Chief Officer | ||
| Erez Raphael, Chairman, CEO and Pres | ||
| Mona Dean, Chief Officer | ||
| Mary Mooney, Vice Marketing | ||
| Limor Drezner, Chief Officer | ||
| Olivier Jarry, President and Chief Commercial Officer | ||
| Omar MD, Chief Officer |
DarioHealth Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is DarioHealth Corp a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.75 | ||||
| Return On Asset | -0.35 | ||||
| Profit Margin | (2.06) % | ||||
| Operating Margin | (1.62) % | ||||
| Current Valuation | 37.92 M | ||||
| Shares Outstanding | 34.1 M | ||||
| Shares Owned By Insiders | 17.71 % | ||||
| Shares Owned By Institutions | 23.57 % | ||||
| Number Of Shares Shorted | 1.92 M | ||||
| Price To Earning | (2.30) X |
Pair Trading with DarioHealth Corp
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if DarioHealth Corp position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in DarioHealth Corp will appreciate offsetting losses from the drop in the long position's value.Moving against DarioHealth Stock
| 0.64 | LH | Laboratory | PairCorr |
| 0.61 | XAIR | Beyond Air | PairCorr |
| 0.55 | HUM | Humana Inc Fiscal Year End 23rd of January 2025 | PairCorr |
| 0.54 | CAH | Cardinal Health | PairCorr |
| 0.49 | VREX | Varex Imaging Corp | PairCorr |
The ability to find closely correlated positions to DarioHealth Corp could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace DarioHealth Corp when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back DarioHealth Corp - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling DarioHealth Corp to buy it.
The correlation of DarioHealth Corp is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as DarioHealth Corp moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if DarioHealth Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for DarioHealth Corp can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DarioHealth Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in DarioHealth Stock, please use our How to Invest in DarioHealth Corp guide.You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DarioHealth Corp. If investors know DarioHealth will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DarioHealth Corp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.93) | Revenue Per Share 0.631 | Quarterly Revenue Growth 1.11 | Return On Assets (0.35) | Return On Equity (0.75) |
The market value of DarioHealth Corp is measured differently than its book value, which is the value of DarioHealth that is recorded on the company's balance sheet. Investors also form their own opinion of DarioHealth Corp's value that differs from its market value or its book value, called intrinsic value, which is DarioHealth Corp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DarioHealth Corp's market value can be influenced by many factors that don't directly affect DarioHealth Corp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DarioHealth Corp's value and its price as these two are different measures arrived at by different means. Investors typically determine if DarioHealth Corp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DarioHealth Corp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.